Eastern Connecticut Health Network, Manchester, Connecticut (Naveed)
Diabetes Care 38 , 10161029 (2015)
In this Review, we summarize the current clinical evidence for GLP-1 receptor agonists and cancer risk, including thyroid, pancreatic, gastrointestinal, and hormone-dependent malignancies
It is a non-Specified Substance, prohibited at all times, both in-competition and out-of-competition, for all athletes under WADA jurisdiction
GLP-1 receptor agonists like Ozempic are typically more effective for weight management because they reduce appetite and slow digestion, whereas SGLT2 inhibitors generally offer only modest weight reduction
There may be subnormal levels of vitamin B 6 due to various factors associated with CKD